Degradation of cross-linked fibrin by matrix metalloproteinase 3 (stromelysin 1): Hydrolysis of the gamma Gly 404-Ala 405 peptide bond

被引:90
作者
Bini, A [1 ]
Itoh, Y [1 ]
Kudryk, BJ [1 ]
Nagase, H [1 ]
机构
[1] UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOL BIOL,KANSAS CITY,KS 66160
关键词
D O I
10.1021/bi960730c
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Matrix metalloproteinases (MMPs) can degrade a number of proteins that constitute the extracellular matrix. Previous studies have shown that atherosclerotic plaques contain substantial amounts of fibrin(ogen)-related antigen, and more recently, MMPs have been identified in such lesions. The hypothesis that MMPs play a role in the degradation of fibrinogen (Fg) and cross-linked fibrin (XL-Fb) was investigated. Fibrinogen became thrombin-unclottable when treated with matrix metalloproteinase 3 (MMP-3, stromelysin 1) but not with matrix metalloproteinase 2 (MMP-2, gelatinase A). Incubation of XL-Fb clots (made with I-125-Fg) With MMP-3 resulted in complete lysis after 24 h. A D monomer-like fragment generated by MMP-3 degradation of fibrinogen, XL-Fb, and fragment DD. Immunoreactivity with monoclonal antibody (MoAb)/4-2 (anti-gamma 392-406) but not with MoAb/4A5 (anti-gamma 397-411) suggested that a major cleavage site was within the sequence participating in the cross-linking of two gamma-chains. NH2-terminal sequence analysis of the gamma-chain of the D monomer-like fragment and of a dipeptide isolated from the MMP-3 digest of XL-fibrin identified the hydrolysis of the gamma Gly 404-Ala 405 peptide bond. These data indicate that the degradation of Fg and XL-Fb by MMP-3 is specific and different from plasmin. This mechanism of fibrinolysis might be of relevance in wound healing, inflammation, atherosclerosis, and other pathophysiological processes.
引用
收藏
页码:13056 / 13063
页数:8
相关论文
共 56 条
[1]  
[Anonymous], 1986, Monoclonal Antibodies: Principles and Practice
[2]  
BILEZIKIAN SB, 1977, BLOOD, V50, P21
[3]  
BINI A, 1987, BLOOD, V69, P1038
[4]   IDENTIFICATION AND DISTRIBUTION OF FIBRINOGEN, FIBRIN, AND FIBRIN(OGEN) DEGRADATION PRODUCTS IN ATHEROSCLEROSIS - USE OF MONOCLONAL-ANTIBODIES [J].
BINI, A ;
FENOGLIO, JJ ;
MESATEJADA, R ;
KUDRYK, B ;
KAPLAN, KL .
ARTERIOSCLEROSIS, 1989, 9 (01) :109-121
[5]   FLOW AND ANTIBODY-BINDING PROPERTIES OF HYDRATED FIBRINS PREPARED FROM PLASMA, PLATELET-RICH PLASMA AND WHOLE-BLOOD [J].
BINI, A ;
CALLENDER, S ;
PROCYK, R ;
BLOMBACK, B ;
KUDRYK, BJ .
THROMBOSIS RESEARCH, 1994, 76 (02) :145-156
[6]  
BINI A, 1995, CIRCULATION S1, V92, P623
[7]  
BINI A, 1996, FASEB J, V10, pA1016
[8]   FIBRIN GEL STRUCTURE AND CLOTTING TIME [J].
BLOMBACK, B ;
OKADA, M .
THROMBOSIS RESEARCH, 1982, 25 (1-2) :51-70
[9]  
BLOMBACK B, 1968, NATURE, V218, P130, DOI 10.1038/218130a0
[10]   FIBRIN IN HUMAN PLASMA - GEL ARCHITECTURES GOVERNED BY RATE AND NATURE OF FIBRINOGEN ACTIVATION [J].
BLOMBACK, B ;
CARLSSON, K ;
FATAH, K ;
HESSEL, B ;
PROCYK, R .
THROMBOSIS RESEARCH, 1994, 75 (05) :521-538